We are very early in the semaglutide world, exciting times ahead!
For sure we still need to find out many related outcomes. Last year it become known that it increases (high relative risk, low absolute risk) non-arteritic anterior ischemic optic neuropathy (NAION), ie sudden, sometimes permanent vision loss. https://www.ema.europa.eu/en/news/prac-concludes-eye-conditi...
Diabetics are already more prone NAION. This studies contribution was to show that diabetics on GLP-1's are MORE prone. It does not show that the general population is more prone when taking GLP-1's.
I didn't check to see if other studies prove that.